Pfizer Prevnar vaccine wins approval for ages 6-17
(Reuters) - Pfizer Inc on Friday said U.S. regulators had approved wider use of its Prevnar 13 vaccine to prevent infections with pneumococcal bacteria, for children and adolescents aged 6 years to 17 years.
The product was already approved in the United States to prevent infections among children aged 6 weeks through 5 years. It is also approved for adults aged 50 and older.
The vaccine protects against infection with 13 strains of the Streptococcus pneumoniae bacterium. The bacterium can cause pneumonia, ear infections and other problems.
Prevnar 13 has annual sales of about $3.5 billion, making it Pfizer's third-biggest brand. It was approved in 2010, and has largely displaced an older vaccine called Prevnar, which protected against only 7 prevalent strains of the bacterium.
(Reporting by Ransdell Pierson; Editing by David Gregorio and Dan Grebler)
- Tweet this
- Share this
- Digg this
- UPDATE 3-Pizza chain Sbarro files for bankruptcy protection
- Northern California unscathed by 6.8 offshore quake
- UPDATE 2-Snowden: Proposed NSA reforms vindicate my data leaks
- Evidence so far does not point to attack on Malaysian plane - sources
- Allianz lead insurer and Willis broker for Malaysia Airlines
The therapy is one of several new blood clotting agents in development that will help hemophilia patients cut by half, or more, the number of regular intravenous infusions they need to prevent traumatic bleeding. People with hemophilia have a fault in a gene that regulates the body's production of proteins called clotting factors. Full Article